Iradimed (IRMD) Equity Average (2014 - 2026)

Iradimed (IRMD) has 13 years of Equity Average data on file, last reported at $96.6 million in Q1 2026.

• Quarterly Equity Average rose 9.19% year-over-year to $96.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $96.6 million (up 9.19% YoY) and the FY2025 annual result came in at $90.7 million, up 14.66% from the prior year.
• Equity Average held at $96.6 million in Q1 2026 per IRMD's latest filing, from $96.5 million in the prior quarter.
• Across five years, Equity Average topped out at $96.6 million in Q1 2026 and bottomed at $64.2 million in Q2 2022.
• The 5-year median for Equity Average is $73.8 million (2024), against an average of $78.8 million.
• The widest annual swing landed in 2022, when Equity Average rose 0.36%; it then increased 19.88% in 2025.
• Tracing IRMD's Equity Average over 5 years: stood at $71.7 million in 2022, then rose by 1.77% to $73.0 million in 2023, then rose by 16.62% to $85.1 million in 2024, then advanced by 13.34% to $96.5 million in 2025, then increased by 0.08% to $96.6 million in 2026.
• Per Business Quant, the three latest IRMD Equity Average figures stand at $96.6 million (Q1 2026), $96.5 million (Q4 2025), and $96.3 million (Q3 2025).

Peer Comparison